We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+29.27%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$363M
AUM Growth
+$103M
Cap. Flow
+$92.4M
Cap. Flow %
25.45%
Top 10 Hldgs %
73.47%
Holding
43
New
11
Increased
12
Reduced
5
Closed
12

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$20M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$19.2M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$15.5M
4
CLDX icon
Celldex Therapeutics
CLDX
+$9.33M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$8.63M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$17.2M
2
EBS icon
Emergent Biosolutions
EBS
+$9.51M
3
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$7.59M
4
STML
Stemline Therapeutics, Inc.
STML
+$6.87M
5
QURE icon
uniQure
QURE
+$5.51M

Sector Composition

Rank Sector Weight
1 Healthcare 86.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$65M 17.89%
4,590,199
+378,800
+9% +$4.55M
SRNE
2
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$38.5M 10.61%
2,186,520
-27,523
-1% -$354K
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$31.5M 8.67%
1,000,000
+679,133
+212% +$20M
IOVA icon
4
Iovance Biotherapeutics
IOVA
$2.1B
$26.8M 7.38%
2,923,065
+773,158
+36% +$8.63M
CASC
5
DELISTED
Cascadian Therapeutics, Inc.
CASC
$21M 5.79%
936,167
+187,561
+25% +$2.97M
ACAD icon
6
Acadia Pharmaceuticals
ACAD
$4.53B
$20.7M 5.71%
+495,000
New +$19.2M
AGEN
7
Agenus
AGEN
$285M
$19M 5.23%
112,046
+7,702
+7% +$1.09M
VNDA icon
8
Vanda Pharmaceuticals
VNDA
$302M
$18.3M 5.03%
+1,438,693
New +$15.5M
LJPC
9
DELISTED
La Jolla Pharmaceutical Company
LJPC
$15M 4.13%
611,999
+150,500
+33% +$3.1M
TLGT
10
DELISTED
Teligent, Inc
TLGT
$11M 3.04%
175,368
+103,277
+143% +$6.98M
CLDX icon
11
Celldex Therapeutics
CLDX
$2.94B
$8.89M 2.45%
+23,490
New +$9.33M
VCYT icon
12
Veracyte
VCYT
$4.52B
$8.45M 2.33%
+758,497
New +$7.47M
PTX
13
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$7.4M 2.04%
125,017
-14,500
-10% -$1.02M
INNL
14
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$7.28M 2%
497,422
+272,422
+121% +$3.02M
SIOX
15
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$6.93M 1.91%
+42,500
New +$7.2M
TNXP icon
16
Tonix Pharmaceuticals
TNXP
$154M
– –
0
– –
NDRM
17
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$5.7M 1.57%
+371,111
New +$5.22M
AVDL
18
DELISTED
Avadel Pharmaceuticals
AVDL
$5.67M 1.56%
267,747
+52,042
+24% +$933K
BLCM
19
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$5.58M 1.54%
26,252
-21,250
-45% -$5.21M
RCPT
20
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$5.04M 1.39%
26,500
-17,500
-40% -$2.89M
HRTX icon
21
Heron Therapeutics
HRTX
$95.4M
$4.67M 1.29%
+150,000
New +$2.82M
ADYX
22
DELISTED
Adynxx Inc
ADYX
$4.22M 1.16%
+13,333
New +$3.94M
VCEL icon
23
Vericel Corp
VCEL
$2.38B
$3.87M 1.07%
1,083,486
+24,666
+2% +$84.5K
ADAP
24
DELISTED
Adaptimmune Therapeutics
ADAP
$3.37M 0.93%
+183,900
New +$3.16M
FBIO icon
25
Fortress Biotech
FBIO
$114M
$3.12M 0.86%
61,969
+21,969
+55% +$1.13M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Avoro Capital Advisors held 43 positions worth $363M, up 39% from $261M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Avoro Capital Advisors deployed $92.4M of net new capital in Q2 2015, opening 11 new positions and adding to 12 existing holdings. Its largest new stake was Acadia Pharmaceuticals: 495,000 shares worth $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 84% a quarter earlier.

On the sell side, the largest reduction was Bellicum Pharmaceuticals, Inc., an estimated $5.21M trimmed.

  • Avoro Capital Advisors's largest Q2 2015 buy was Acadia Pharmaceuticals: 495,000 shares worth $20.7M.
  • Avoro Capital Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q2 2015, an estimated $20M increase.
  • Avoro Capital Advisors's biggest Q2 2015 reduction was Bellicum Pharmaceuticals, Inc., cutting an estimated $5.21M.
  • Avoro Capital Advisors fully exited Celgene Corp in Q2 2015, selling an estimated $17.2M.
  • Avoro Capital Advisors's ten largest holdings make up 73% of its $363M portfolio in Q2 2015.
  • Avoro Capital Advisors opened 11 new positions and closed 12 in Q2 2015.
  • Avoro Capital Advisors's portfolio value rose 39% quarter-over-quarter to $363M.

Based on Avoro Capital Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.